MedBen Rx Blog
Cutting Specialty Drug Costs Without Cutting Access
Specialty medications continue to drive a disproportionate share of prescription drug costs – often accounting for 60% or more of a pharmacy plan’s total spend. MedBen Rx’s Benefit Preservation helps plans manage these expenses without compromising...
Major PBMs Are Blocking Biosimilar Savings, but MedBen Rx Offers a Better Path
The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow... in no small part because major PBMs are stifling uptake. Fortunately,...
High-Value Formulary Helps Members Resist the Pharma Ad Blitz
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
Reclaim Your Prescription Drug Spend with Smarter Pharmacy Benefits
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...
Price Check: How the U.S. Compares Globally on Prescription Costs
A recent Statista article examines the disparity in prescription drug spending across countries. The Organisation for Economic Co-operation and Development (OECD) ranks the United States highest in average spending, at $1,218 per resident – over $200 more than...
Prescription Drug Spending Surges in 2024, Led by GLP-1s
Prescription drug spending in the U.S. climbed 10.2% in 2024, reaching nearly $806 billion, according to a report from the American Society of Health-System Pharmacists. A significant portion of this growth is attributed to the rapid rise of...
Momentum Grows Against PBM-Owned Pharmacies
On April 16, Arkansas became the first state to ban pharmacy benefit managers (PBMs) from acquiring an interest in – or otherwise directly or indirectly holding a permit for the retail sale of – prescription drugs, including mail-order...
REMINDER: Stelara Biosimilar Available through MedBen Rx
Earlier this month, MedBen Rx clients and their brokers were emailed about an opportunity to receive preferred pricing for the biosimilar for the anti-inflammatory medication Stelara. Depending on the dosage, this biosimilar can reduce the cost of the medication by...
JPMorgan Sued for Allowing Inflated Drug Prices through its PBM
Current and former employees are suing the financial services firm JPMorgan for allowing inflated drug prices through its partnership with pharmacy benefits manager (PBM) CVS Caremark. The plaintiffs claim that poor PBM oversight led to unnecessarily high prescription...
Need to Submit a RxDC Report? MedBen Has You Covered
As you may recall, the Consolidated Appropriations Act of 2021 (CAA) requires group health plans to submit to the Centers for Medicare & Medicaid Services information about prescription drugs and health care spending. This data submission is called RxDC (for...
Benefit Preservation Helps Lower Specialty Drug Spend
High-cost specialty drugs can make up more than 60% of a health plan’s pharmacy costs. MedBen Rx’s benefit preservation program is designed to make certain that members have continued access to medications while reducing specialty drug spend to the greatest...
MedBen Benefits Advisory Conference Explores the State of the Industry
Over 70 guests from seven states attended the MedBen 2025 Benefits Advisory Conference on January 30. Featuring some of the most respected names in the industry, this invitation-only event provided brokers with an extensive look at the state of benefits...